4D pharma this morning has announced a research collaboration and option to license agreement with Merck & Co (MSD) potentially worth up to $1bn to discover and develop live biotherapeutics (LBPs) for vaccines. This represents a substantial milestone for the Group, adding concrete endorsement for the MicroRx® platform from a leading industry partner, and illustrates the platform’s ability to create nearand long-term value.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
MSD platform collaboration: a good strategic fit
- Published:
08 Oct 2019 -
Author:
Edward Thomason -
Pages:
3
4D pharma this morning has announced a research collaboration and option to license agreement with Merck & Co (MSD) potentially worth up to $1bn to discover and develop live biotherapeutics (LBPs) for vaccines. This represents a substantial milestone for the Group, adding concrete endorsement for the MicroRx® platform from a leading industry partner, and illustrates the platform’s ability to create nearand long-term value.